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Caroline Hall 
Senior Honors Project 
A Putative Dual Role for Yorkie in Hippo pathway Signaling  
Abstract 
The Hippo pathway inactivates genes involved in organ size and when aberrant, can lead 
to cancer. To control organ size, the Hippo pathway inhibits Yorkie (Yki), a transcriptional co-
activator that works with Scalloped (Sd), a DNA binding protein. When active, Yki translocates 
into the nucleus and initiates transcription. Conversely, when inactive, Yki remains in the 
cytoplasm. However, my work shows that cytoplasmic, inactive Yki interacts with other proteins 
in the Hippo pathway by recruiting them to the plasma membrane. Accordingly, this study 
challenges the notion that cytoplasmic Yki is inactive and instead, may play a dual role in the 
Hippo pathway.     
Introduction 
Significance  
More than any other time in our history, Americans feel the effects of cancer, with every 
1 in 4 men and 1 in 5 women dying from cancer annually10. Whether an individual suffered from 
cancer personally, or knows someone close who suffered, cancer has touched almost all of our 
lives. So, it is no surprise that cancer research in the scientific community has become a 
burgeoning field of study.  
As an undergraduate student, I began my research on cancer through several lecture 
courses, which led me into Dr. Pam Vanderzalm’s fruit fly, or Drosophila melanogaster, lab at 
John Carroll University (JCU). Dr. Vanderzalm’s lab studies a cellular pathway that controls 
some of the biological mechanisms related to cancer development, including cell contact 
inhibition and organ size control14. This cellular pathway, called the Hippo pathway, employs 
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several proteins involved in cellular signaling for regulation of cell proliferation and cell death, 
including the protein YAP (in humans) or yorkie, (Yki) in fruit flies (Figure 1). The Hippo 
pathway is highly evolutionarily conserved5, and thus, human Hippo pathway genes have 
homologs in D. melanogaster. Using D. melanogaster as a model organism, I conducted a series 
of experiments questioning the proposed relationship of Yki to other proteins within the Hippo 
pathway in order to postulate a new, putative role for Yki’s cellular function.   
 
Figure 1: Major Proteins in the Phosphorylation Cascade of the Hippo Signaling Pathway 
Basic Cancer Biology  
The ubiquitous and menacing presence of cancer within our society has created the need 
for basic research into the mechanisms by which cancer functions. This basic research exposes 
the aberrant nature of cancer cells and thereby the eight hallmarks of cancer, most of which 
present themselves in cancerous cells1. The Hippo pathway functions to regulate both 
proliferative signaling and growth suppression14, and when aberrant, these functions become two 
of the eight hallmarks of cancer. Proliferative signaling may become abnormal when a cell 
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continuously divides, creating a large mass of cells called a tumor. These cells continue to divide 
despite efforts to suppress growth, like cell-contact inhibition. Normal cell-contact inhibition 
occurs when healthy cells stop dividing when the cells contact too many neighboring cells. This 
growth suppression response occurs in a healthy cell by cell-to-cell communication, facilitated 
by protein factors released from the cells when they grow and start to become too crowded. 
However, cancerous cells continue to divide despite this cell-contact inhibition, allowing for the 
growth of a tumor.  Once the cells continuously proliferate and fail to respond to growth 
suppressors, the other six hallmarks of cancer may, in any order, occur in the cell1. These six 
other hallmarks include: resisting cell death, enabling replicative immortality, inducing 
angiogenesis, activating invasion and metastasis, reprogramming of energy metabolism, and 
evading immune destruction1. After the appearance of any combination of several hallmarks, the 
cell is considered cancerous.  
The Hippo pathway’s Role in Cancer 
Recent studies implicate the Hippo pathway in both proliferative signaling and growth 
suppression, via regulation of organ size and role in contact inhibition, respectively14. In healthy 
cells, Hippo pathway signaling is off to allow the cells to divide until the cells reach the proper 
size of the organ that they compose, a liver, for example14. The Hippo pathway is then activated 
once the cells have a large proportion of neighboring cells (i.e. contact inhibition) so that the 
cells stop dividing once they reach the proper organ size14. Thus, when certain steps of the Hippo 
pathway fail to function normally, inappropriate growth and cancer can result14. Additionally, 
when the Hippo pathway fails to function completely or is lost, known cancers develop2.   
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Canonical Hippo pathway Signaling 
Normal Hippo pathway functioning occurs via specific signals, leading to a cascade of 
events, via proteins, within the cell (Figure 1). In D. melanogaster, the major proteins in the 
Hippo pathway include: Expanded (Ex), Kibra (Kib), Merlin (Mer), Tao-1, Hippo (Hpo), 
Salvador (Sav), Warts (Wts), Mats (Mats), and Yorkie (Yki). The Hippo pathway becomes 
activated through unknown mechanisms including known receptor protein Fat14, G-coupled 
protein receptor signaling (in vertebrates) and changing cytoskeletal tension2. After activation, 
Ex, Kib, and Mer, which are all apically located proteins (located near the plasma membrane in 
the cell cortex), act as upstream regulators of the kinase cascade6, 9. The significance of the 
localization of these proteins at the apical membrane is still not understood3, but may prove 
important in the future. In the kinase cascade, a series of proteins act to either activate or 
inactivate, via phosphorylation, downstream proteins, transferring the signal throughout the 
cell’s cytoplasm and into the nucleus1. The Hippo pathway kinase cascade includes the proteins 
Tao-1, Hpo, Sav, Wts, Mats, and Yki3, 5 (Figure 1). Hpo and Sav form a complex, and when Hpo 
is phosphorylated by Tao-1, Hpo in turn phosphorylates Sav3, 5. The active Hpo/Sav complex 
allows Hpo to phosphorylate Wts and Mats4. Wts and Mats form a complex that enhances the 
kinase activity of Wts11, allowing Wts to phosphorylate Yki. Phosphorylated Yki renders Yki 
inactive4 via cytoplasmic retention14.  
As the downstream target molecule of the Hippo signaling pathway, Yki has a primary 
function in transcription; more specifically, as a transcriptional co-activator7, 12. When the Hippo 
pathway is not functioning, Yki may enter the nucleus and carry out this canonical role. As a 
transcriptional co-activator, Yki requires a specific binding partner, the transcription factor 
Scalloped (Sd)7,12, which is directly bound to DNA. Upon binding of Yki to Sd, transcription of 
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the DNA downstream of the Yki/Sd complex occurs, which includes genes that promote cell 
growth and inhibit cell death. For example, one Yki target gene encodes for a protein that 
inhibits cell death, called diap112, 14. When Yki is not functioning in the nucleus, Yki is generally 
considered to be “inactive” in the cytoplasm14.  
The Importance of Localization in the Hippo pathway 
 While the Hippo pathway often does function according to the canonical model, recent 
studies suggest that Hippo pathway proteins may regulate Yki by methods other than 
phosphorylation, depending on the cellular localization of the proteins involved3. To start, 
upstream regulators of the Hippo pathway, which are located in the cell’s cytoplasm near the 
plasma membrane, may directly inactivate Yki by recruiting Yki to this area of the cell, called 
the cell cortex3. Ex has been shown to directly bind Yki2 and form a complex with Hpo and 
Wts3. Thus, the Hippo pathway may control Yki activity through mechanisms other than 
phosphorylation, blurring the lines between the upstream and downstream designations proposed 
by the canonical pathway. However, the mechanism by which the cell regulates Yki activity 
depends upon the localization of Yki within the cell; the closer Yki is to the “upstream” proteins 
of the pathway (Ex, Mer), the more likely these proteins will directly control Yki, while the 
further Yki is from the “upstream” pathway proteins, the less likely Yki will be phosphorylated3. 
Furthermore, control of Yki in this secondary manner may result from the location of “upstream” 
pathway proteins near the adherens junction (AJ) in D. melanogaster epithelial cells3. Current 
research suggests that the AJ may receive signals from neighboring cells, such as signals for 
growth suppression via contact inhibition, that regulate proteins of the Hippo pathway3. In order 
for this regulation to occur, however, “upstream” Hippo pathway proteins must localize near the 
AJ, in the cell cortex3. Accordingly, the location of Hippo pathway proteins plays a role in the 
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regulation of Yki in the cell, and plays an important role in the signaling events of the pathway. 
In addition to the importance of localization of other Hippo pathway proteins, the location of Yki 
within the cell also impacts Hippo pathway activity. Canonically, active Yki maintains a role 
within the nucleus as a transcriptional co-activator, while inactive Yki stays within the 
cytoplasm, where Yki may or may not play a secondary role (P. Vanderzalm, unpublished 
results).  
Dual Role for Cytoplasmic Yorkie  
Whether Yki is truly inactive within the cytoplasm has recently been called into question. 
Dr. Vanderzalm’s lab has postulated that cytoplasmic Yki might have another role in the cell, 
unrelated to its nuclear role. One piece of evidence that led to this hypothesis is that the upstream 
regulators of the pathway, namely, the proteins Ex, Kib, and Mer, are all located near the apical 
membrane of the cell3, 9. When Yki is cytoplasmic, a significant amount of it is also found in this 
apical region13. In order to understand the significance of this Yki localization at the cell 
membrane, Dr. Vanderzalm eliminated the transcriptional binding site of Yki, so that Yki failed 
to act in its role as a transcriptional co-activator but could still remain active in the cytoplasm. 
This “transcriptionally-dead” version of Yki seemed more tightly associated with the plasma 
membrane than wild-type Yki, and its overexpression led to increased levels of Ex and Diap1 at 
the apical membrane, post-translationally (unpublished results). Accordingly, I want to know if 
Yki is sufficient to recruit Ex, Diap1, and other Hippo pathway proteins to the apical plasma 
membrane, further elucidating Yki’s cytoplasmic function. 
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Myristoylation and Experimental Procedure 
 To determine if Yki plays a dual role in the cytoplasm, I used a chemically modified 
version of Yki, myristoylated Yki (Myr-Yki). Myristoylation specifically tethers Yki to the inner 
leaflet of the cell’s plasma membrane.  This means I can locate Yki at any given time in the cell, 
and thereby, observe if Yki is sufficient to recruit other proteins of the pathway to its location. I 
transfected this version of Yki into D. melanogaster S2 cells, along with the DNA for a protein 
of interest (Ex, Mer, Hpo, Diap1, or Sd). Next, I analyzed the expression of the proteins 
produced by the transfected DNA by immunofluoresence on a confocal microscope. 
Surprisingly, I observed that Yki is sufficient to recruit not only Ex, Mer, and Hpo, but also 
Diap1 and Sd to the plasma membrane. Accordingly, I propose that Yki plays a dual role in the 
cytoplasm and most likely, this role involves stabilizing other proteins.  
Methods 
Acquiring DNA Constructs 
The Vanderzalm lab already had created all of the DNA constructs when I arrived. The 
DNA constructs used encoded epitope-tagged fusion proteins to facilitate detection by 
immunostaining. Myr-Yki expression was under the control of a UAS promoter, and was driven 
by Ubiquitin-Gal44, while other constructs were expressed under the control of an actin 
promoter. Constructs used included UAS-FLAG-myr-Yki, Ubiquitin-Gal4, empty FLAG vector, 
HA-Ex, HA-Mer, V5-Wts, Myc-Hpo, HA-Sd, and HA-Diap1. Briefly, 48 hours after 
transfection, I fixed and stained the cells with primary antibodies against the epitope tags, and 
used fluorescently labeled secondary antibodies to visualize the proteins.  
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Cell Transfection 
 D. melanogaster S2 cells were maintained in Schneider’s Media (S2 media) with 10% 
FBS (Fetal Bovine Serum) and split 1:1 or 1:4 when 90-100% confluent. To prepare for 
transfection, I split the cells 1:1 the day prior. On the day of transfection, I made a mixture of 
Schneider’s Media with 10% IMS (Insect Medium Supplement) and DDAB 
(Dimethyldioctadecylammonium bromide) to act as a lipofection agent in a 2:1 ratio. The 
lipofection agent allowed for introduction of exogenous DNAs into the cells8. While the S2 
media-DDAB mixture incubated for 5 minutes, I counted the S2 cell density and calculated the 
volume of cells to add to Schneider’s Media with 10% IMS to create a ~2-4 x 106 cells/well 
solution. Next, I prepared separate microfuge tubes for the transfected, exogenous DNAs by 
adding ~150 uL of the S2 media-DDAB mixture. To this 0.5 ug of each DNA was added to each 
transfection. The S2 media-DDAB-DNA mixture incubated for 15 minutes, during which time I 
added the calculated volume of cells and media (to a total of 2 mL) to add to a 6-well plate. After 
15 minutes, I added the whole volume of the S2 media-DDAB-DNA mixture to a well drop-
wise. To mix, I gently tipped the plate to each side. The cells then incubated for 4-6 hours at 
25°C, at which time I removed the media and cells from the 6-well plate and added them to a 15 
mL conical vial. I centrifuged the cells at 1000rpm for 5 minutes at room temperature, removed 
the S2 media containing IMS (supernatant) via pipette, added 2 mL of S2 media containing 10% 
FBS, transferred the cells to 2 mL microfuge tubes, resuspended the cells, then added them to a 
fresh 6-well plate. The cells then incubated for ~2 days at 25°C.  
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Indirect Immunostaining  
Suspension Staining 
 The transfected cells were harvested from 6-well plates into 2 mL microfuge tubes and 
were centrifuged at 3000 rpm for 1 minute at room temperature. The supernatant was removed 
via pipette, and the cells were resuspended in 400 uL of fresh 2% paraformaldehyde (PFA) to fix 
them. The cell-PFA mixture incubated at room temperature for 10-15 minutes. After the 
incubation, cells were centrifuged at 3000rpm for 1 minute, the PFA was removed via pipette, 
and the cells were washed twice with 1mL 1X PBS. A mixture of 250 uL PBS, 0.1% Triton-X-
100, and 1% normal goat serum (PTN) plus the appropriate primary antibody at the appropriate 
dilution was added to the cells and allowed to stain for ~1 hour at room temperature on the 
rocker. The primary antibodies used included: 1:1000 rabbit anti-HA (Rockland), 1:20,000 
mouse anti-Myc (Cell Signaling), 1:1000 mouse anti-V5 (Pierce), 1:50,000 mouse anti-Flag 
(Sigma), and/or 1:1000 rabbit anti-Flag (Rockland). After staining, the cells were rinsed once 
with 1 mL 1X PBS, and stained in secondary antibody with PTN and incubated on the rocker for 
~1 hour in the dark. Secondary antibodies (Jackson Immunochemicals) were all used at 1:1000 
and included donkey anti-mouse or donkey anti-rabbit Cy3 for Flag, and donkey anti-rabbit 
Alexa-488/FITC for HA, and donkey anti-mouse Alexa-488/FITC for V5 and Myc. DAPI at 
1:5000 was added during the incubation in secondary antibody. After staining in secondary, the 
cells were rinsed with 1 mL 1X PBS and resuspended in 25 uL of Invitrogen ProLong AntiFade 
mounting media. The whole volume of cells and media was then pipetted onto a glass slide, 
covered with a coverslip, and stored at 4°C in the dark.  
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Staining Cells on Concanavalin A-Treated Coverslips 
First, I diluted the Concanavalin A (ConA) to a working concentration of 0.5 ug/mL in 
water. I distributed the ConA in a thin layer (~25 uL per coverslip) onto each coverslip and 
allowed the coverslips to dry in the fume hood for 1 hour. Next, I spun down the transfected cells 
in the 2 mL microfuge tubes and resuspended the cells in 200 uL of S2 media containing 10% 
FBS. I pipetted this whole volume onto the coverslip with ConA to allow adherence for one hour 
and covered to prevent evaporation. I gently washed the cells twice with 1X PBS. To fix the 
cells, I added 200 uL of 2% PFA onto each coverslip and incubated 10-15 minutes at room 
temperature. I washed once more with 1X PBS. I stained the cells in primary with PTN and the 
appropriate primary antibody at the same dilution as the suspension staining protocol. I covered 
the coverslips and incubated the stained coverslips for ~1 hour at room temperature. I washed 
once more with 1X PBS and incubated the cells in secondary antibody with PTN as outlined in 
the suspension staining protocol for ~1 hour in the dark and at room temperature. After staining, 
I washed the cells twice with 1X PBS and placed the coverslips cell-side down onto slides with 
25 uL Invitrogen ProLong AntiFade mounting media. The slides were stored at 4°C in the dark. 
Fluorescence Microscopy 
 I qualitatively analyzed the cells at 1000X magnification under the Olympus BX-60 
compound fluorescene microscope at JCU. I used the correct light filters to visualize DAPI, Cy3, 
and Alexa-488 or FITC fluorescence, thereby viewing the cell’s DNA, myr-Yki, and the Hippo 
protein of interest, respectively. However, the compound fluorescence microscope does not have 
a camera apparatus for fluorescent light, so I performed imaging at the confocal microscope in 
the Neuroscience Department of Case Western Reserve University.  
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Confocal Microscopy 
 I performed further qualitative research at 1000X magnification using the Zeiss LSM 510 
Meta laser-scanning confocal microscope at the Department of Neuroscience at Case Western 
Reserve University. I used optical sectioning imaging to view the cells on the z-axis and used 
ImageJ imaging software (NIH) to process the images. Optical sectioning allowed me to 
ascertain co-localization of two proteins within a single cell. I imaged two or three cells in each 
experimental condition for a representative sample of qualitative data.  
Results 
Upstream Hippo pathway Proteins Co-Localize with Myristoylated Yorkie at the Plasma 
Membrane 
 To determine if Myr-Yki was sufficient to recruit candidate proteins to the cell’s plasma 
membrane, I transfected D. melanogaster S2 cells with DNA constructs corresponding to Myr-
Yki and one candidate protein, for each protein in turn. I then used staining techniques and 
subsequent immunofluoresence to detect the expression patterns of the proteins, using DAPI as a 
marker for the nucleus. The upstream Hippo pathway proteins scrutinized included: Ex, Hpo, and 
Mer. To begin, Ex co-localizes with Myr-Yki at the plasma membrane of the cell, meaning that 
Yki is sufficient to recruit Ex to the plasma membrane (Fig. 1). Since Ex alone appears in 
punctae diffusely throughout the cytoplasm of the cell (Fig. 1A and B), and Ex in the presence of 
Myr-Yki re-locates to the cell’s plasma membrane (Fig. 1D and E), it follows that Yki recruits 
Ex to the plasma membrane. Similarly, Hpo also co-localizes with Myr-Yki at the plasma 
membrane of the cell, meaning that Yki is also sufficient to recruit Hpo to the plasma membrane 
(Fig. 2). Without Myr-Yki, Hpo localizes throughout the cell’s cytoplasm and is faintly seen in 
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the nucleus (Fig. 2A and B), but, when Myr-Yki and Hpo are introduced to the cell together, Hpo 
moves to the cell’s plasma membrane (Fig 2D and E). Thus, Yki must be sufficient to recruit 
Hpo to the plasma membrane. In addition, Mer also co-localizes with Myr-Yki at the cell’s 
plasma membrane, meaning that Yki is also sufficient to recruit Mer to the plasma membrane 
(Fig. 3). When introduced to the cell alone, Mer localizes in punctae diffusely in the cytoplasm 
(Fig. 3A and B), but when introduced with Myr-Yki, Mer moves to the plasma membrane, where 
Myr-Yki localizes (Fig. 3D and E). Accordingly, Yki must be pulling Mer from the cytoplasm to 
the cell’s plasma membrane. Since Dr. Vanderzalm’s lab had previously demonstrated that Yki 
can co-immunoprecipitate with Ex, Mer, and Hpo (unpublished data), Yki’s ability to re-locate 
Ex, Hpo, and Mer to the plasma membrane was consistent with these results.  
Associated Hippo pathway Proteins Co-Localize with Myristoylated Yorkie at the Plasma 
Membrane 
 Yki exhibited a similar ability to recruit Sd and Diap1, proteins associated with the Hippo 
pathway, which came as a surprise. Sd is a transcription factor bound to the promoter region of 
Yorkie target genes. Accordingly, I expected Sd to remain bound to the target DNA even in the 
presence of Myr-Yki, and was using Sd as a negative control. As expected, Sd localized to the 
cell’s nucleus in the absence of Myr-Yki (Fig. 4A and B), but surprisingly relocates to the 
plasma membrane in the presence of Myr-Yki (Fig. 4D and E). Therefore, Sd must have a 
stronger binding affinity for Yki than for DNA, since Myr-Yki is clearly sufficient to recruit Sd 
to the cell’s plasma membrane.  
 Expanded, in addition to being an upstream activator of the Hippo pathway, is also a 
well-established Yorkie target gene5. However, preliminary results from the Vanderzalm lab 
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suggested that Yki was able to promote Ex protein levels at the membrane post-transcriptionally. 
In order to ascertain if other Yki target genes could be similarly affected by Yki post-
transcriptionally, I tested whether Myr-Yki was sufficient to recruit Diap1 to the plasma 
membrane. Diap1 is a Yki target gene that prevents apoptosis from occurring in cells11. Since 
Diap1 is a transcriptional output, rather than a Hippo signaling pathway protein, I expected that 
Diap1 might not be recruited by Yki at all. Without Myr-Yki, Diap1 appears diffusely 
throughout the entire cell, nucleus and cytoplasm (Fig. 5A and B). When co-transfected with 
Myr-Yki, Diap1 moves to the cell’s plasma membrane, co-localizing with Myr-Yki (Fig. 5D and 
E). Therefore, Yki is sufficient to recruit Diap1 to the cell’s plasma membrane.  
Discussion  
Yki’s Dual Role in the Cytoplasm 
 Yki’s ability to recruit Ex, Mer, Hpo, Sd, and Diap1 to the plasma membrane while in its 
“inactive”, unphosphorylated version in the cytoplasm suggests a second role for Yki, distinct 
from its nuclear role. While Dr. Vanderzalm previously showed that Yki binds Ex, Mer, Sd, and 
Hpo in co-immunoprecipitation experiments (unpublished data), there was no evidence to 
support if Yki would recruit Diap1. Also, it was uncertain whether Yki that was specifically 
found in the cytoplasm would be capable of binding Sd. In fact, since Sd and Diap1 do not 
participate in the Hippo pathway signaling cascade, I did not expect co-localization of Sd and 
Diap1 with Myr-Yki. However, I was surprised to discover that Myr-Yki was sufficient to recruit 
both Sd and Diap1 to the plasma membrane.  Furthermore, Myr-Yki’s ability to bind to Ex, Mer, 
Hpo, Sd, and Diap1 and recruit them to the plasma membrane suggests that Yki’s cytoplasmic 
role may involve stabilizing these proteins or the complexes they form.  
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Significance  
 While the canonical model of Hippo pathway signaling designates cytoplasmic Yki as 
inactive, my findings suggest that cytoplasmic Yki plays a functional role with Hippo pathway 
and associated proteins. Other studies support my findings, proposing that the localization of Yki 
(via protein-protein interactions) to the cell cortex functions as a mechanism of control of the 
signaling pathway2. Specifically, Yki directly binds Ex, and forms a complex with Hpo and 
Wts2. Since Ex localizes near the cell cortex, the entire protein-protein complex is recruited to 
the cell cortex, rendering Yki “inactive” and turning off the Hippo pathway. Similarly, another 
well-studied signaling pathway, the Wnt signaling pathway, is also regulated by localization of 
one of its key proteins, beta-catenin, to the cell cortex1, Thus, cellular localization of proteins in a 
signaling pathway commonly acts as a key mechanism of controlling the pathway itself. 
Accordingly, cellular localization of Yki and Yki’s ability to recruit other proteins to that 
location suggests that Yki might actually play a role not only in stabilizing these proteins, but 
also in regulating the pathway itself. Moreover, since the Hippo pathway can cause 
tumorigenesis when aberrant, Yki’s role and location in the Hippo pathway becomes especially 
crucial. Therefore, whether or not Yki binds Ex, Mer, Hpo, Sd, or Diap1 directly, or indirectly 
via another protein, is an important question. In order to further elucidate Yki’s cytoplasmic role, 
this question of direct or indirect binding would need an answer. Accordingly, in the future, Dr. 
Vanderzalm’s lab would need to perform GST pull down assays with Yki and Mer, Hpo, and 
Diap1 (Ex and Sd are already known as direct interactors2,7,12). Whether or not Yki’s dual role in 
the cytoplasm could contribute to aberrant cell growth is also still unknown. However, given 
Yki’s role in the Hippo pathway and when malfunctioning, tumorigenesis, Yki’s role in the 
cytoplasm could contribute to this abnormal growth.  
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Figure 2. Myristoylated Yki Recruits Hpo to the Plasma Membrane 
A-B. Z-Stack of 1000X Magnification of S2 cells expressing Myc-Hpo  
A.Myc-Hpo localizes to the cytoplasm, and is faintly seen in the nucleus 
B.DAPI stain indicates the nucleus, showing predominant cytoplasmic 
localization of Hpo 
C-E. Z-Stack of 1000X Magnification of S2 cells expressing Myc-Hpo and 
Flag-Myr-Yki 
C. Flag-Myr-Yki localizes to the	  plasma membrane 
D. Myc-Hpo localizes to the plasma membrane in the presence of Myr-Yki  
E. Merge of Flag-Myr-Yki channel and Myc-Hpo channel, together with DAPI, 
to show clear co-localization of Myr-Yki and Hpo at the plasma membrane	  	  	  	  
Figure 1. Myristoylated Yki Recruits Ex to the Plasma Membrane 
A-B. Z-Stack of 630X Magnification of S2 cells expressing HA-Ex  
A.HA-Ex localizes to the cytoplasm in punctae 
B.DAPI stain indicates the nucleus, showing distinct cytoplasmic localization 
of Ex 
C-E. Z-Stack of 630X Magnification of S2 cells expressing HA-Ex and Flag-
Myr-Yki 
C. Flag-Myr-Yki localizes to the plasma membrane 
D. HA-Ex localizes to the plasma membrane in the presence of Myr-Yki  
E. Merge of Flag-Myr-Yki channel and HA-Ex channel, together with DAPI, to 
show clear co-localization of Myr-Yki and Ex at the plasma membrane  	  
Figure 3. Myristoylated Yki Recruits Mer to the Plasma Membrane 
A-B. Z-Stack of 1000X Magnification of S2 cells expressing HA-Mer  
A.HA-Mer localizes to the cytoplasm in punctae 
B.DAPI stain indicates the nucleus, showing distinct cytoplasmic localization 
of Mer 
C-E. Z-Stack of 1000X Magnification of S2 cells expressing HA-Mer and 
Flag-Myr-Yki 
C. Flag-Myr-Yki localizes to the plasma membrane 
D. HA-Mer localizes to the plasma membrane (and cytoplasm) in the presence 
of Myr-Yki  
E. Merge of Flag-Myr-Yki channel and HA-Mer channel, together with DAPI, 
to show clear co-localization of Myr-Yki and Mer at the plasma membrane  	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Figure 4. Myristoylated Yki Recruits Sd to the Plasma Membrane 
A-B. Z-Stack of 1000X Magnification of S2 cells expressing HA-Sd  
A.HA-Sd localizes to the nucleus 
B.DAPI stain indicates the nucleus, showing distinct nuclear localization of Sd 
C-E.  Z-Stack of 1000X Magnification of S2 cells expressing HA-Sd and Flag-
Myr-Yki 
C. Flag-Myr-Yki localizes to the plasma membrane 
D. HA-Sd localizes to the plasma membrane in the presence of Myr-Yki  
E. Merge of Flag-Myr-Yki channel and HA-Sd channel, together with DAPI, 
to show clear co-localization of Myr-Yki and Sd at the plasma membrane  	  	  	  	   Figure 5. Myristoylated Yki Recruits Diap1 to the Plasma Membrane A-B. Z-Stack of 1000X Magnification of S2 cells expressing HA-Diap1 
A.HA-Diap1localizes to the nucleus and cytoplasm 
B.DAPI stain indicates the nucleus, showing diffuse localization of Diap1 
throughout the cell 
C-E. Z-Stack of 1000X Magnification of S2 cells expressing HA-Diap1 and 
Flag-Myr-Yki 
C. Flag-Myr-Yki localizes to the plasma membrane 
D. HA-Diap1 localizes to the plasma membrane in the presence of Myr-Yki  
E. Merge of Flag-Myr-Yki channel and HA-Diap1 channel, together with 
DAPI, to show clear co-localization of Myr-Yki and Diap1 at the plasma 
membrane  
 	  	  	  	  
